Personalized Peptide Vaccine Shows Promise for Advanced Pancreatic Cancer
A personalized neoantigen peptide vaccine (iNeo-Vac-P01) was safe and showed immune activation in advanced pancreatic cancer patients, with one patient achieving remarkable T-cell expansion and 21-month survival on vaccine therapy.
Quick Facts
What This Study Found
Personalized neoantigen vaccine was safe in pancreatic cancer with low tumor mutation burden; one patient showed dramatic antigen-specific T-cell expansion from 0% to ~100% with 21-month vaccine-associated survival.
Key Numbers
7 patients; up to 20 peptides each; TMB <10; OS 24.1 mo; vaccine OS 8.3 mo; PFS 3.1 mo; P01: 21 mo, TCR 0→~100%
How They Did This
Retrospective study of 7 advanced pancreatic cancer patients. Up to 20 neoantigen peptides per patient identified by iNeo-Suite pipeline. Multiple vaccine doses administered. Immune monitoring via ELISpot and flow cytometry pre/post-vaccination.
Why This Research Matters
Pancreatic cancer has a 5-year survival rate under 10% and limited treatment options. This is among the first studies showing personalized neoantigen vaccines can work even in cancers with low mutation burden.
The Bigger Picture
Pancreatic cancer has been resistant to immunotherapy approaches that work in other cancers. Demonstrating that personalized peptide vaccines can activate meaningful immune responses — even in a cancer with few mutations — opens a new avenue for treating one of the deadliest cancers.
What This Study Doesn't Tell Us
Very small sample (n=7). Retrospective design. No control group. Heterogeneous patient population. Cannot definitively attribute survival to vaccine therapy.
Questions This Raises
- ?Would a randomized trial confirm survival benefit?
- ?Can the T-cell expansion seen in the best responder be replicated in more patients?
- ?Would combining neoantigen vaccines with checkpoint inhibitors improve outcomes?
Trust & Context
- Key Stat:
- T-cell clone: 0% to ~100% In the best responder, who survived 21 months on vaccine therapy for advanced pancreatic cancer
- Evidence Grade:
- Very small retrospective study (n=7) providing proof-of-concept. Individual case results are dramatic but require larger trial confirmation.
- Study Age:
- Published in 2021, representing early clinical experience with personalized neoantigen vaccines in pancreatic cancer.
- Original Title:
- A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.
- Published In:
- Frontiers in immunology, 12, 691605 (2021)
- Authors:
- Chen, Zheling, Zhang, Shanshan, Han, Ning, Jiang, Jiahong, Xu, Yunyun, Ma, Dongying, Lu, Lantian, Guo, Xiaojie, Qiu, Min, Huang, Qinxue, Wang, Huimin, Mo, Fan, Chen, Shuqing, Yang, Liu
- Database ID:
- RPEP-05317
Evidence Hierarchy
Frequently Asked Questions
How does a personalized cancer vaccine work?
Scientists sequence the patient's tumor DNA to find unique mutations. They then create custom peptides matching these mutations and vaccinate the patient, training their immune system's T cells to recognize and attack cells carrying those specific mutations.
Why is this important for pancreatic cancer?
Pancreatic cancer is one of the deadliest cancers with few effective treatments. It typically has few mutations, which makes it a challenging target for immunotherapy. This study shows that personalized vaccines can still activate strong immune responses even in cancers with low mutation burden.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05317APA
Chen, Zheling; Zhang, Shanshan; Han, Ning; Jiang, Jiahong; Xu, Yunyun; Ma, Dongying; Lu, Lantian; Guo, Xiaojie; Qiu, Min; Huang, Qinxue; Wang, Huimin; Mo, Fan; Chen, Shuqing; Yang, Liu. (2021). A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.. Frontiers in immunology, 12, 691605. https://doi.org/10.3389/fimmu.2021.691605
MLA
Chen, Zheling, et al. "A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.." Frontiers in immunology, 2021. https://doi.org/10.3389/fimmu.2021.691605
RethinkPeptides
RethinkPeptides Research Database. "A Neoantigen-Based Peptide Vaccine for Patients With Advance..." RPEP-05317. Retrieved from https://rethinkpeptides.com/research/chen-2021-a-neoantigenbased-peptide-vaccine
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.